Partners
OutMARCH is an international research consortium funded under the European Union’s Horizon Europe EIC Pathfinder programme. We are a team of researchers, clinicians, and industry scientists from the Netherlands, Germany, and Switzerland, working together to develop a treatment for cancer, targeting cancer-driving proteins. Our partners bring a range of complementary expertise: from antibody engineering and cancer biology to structural biology and drug development. All with the shared goal of turning the project into something that could one day benefit patients.
Meet our members below!
University Medical Center Utrecht, the Netherlands
UMCU is the academic hospital of Utrecht University, where clinical care and research go hand in hand. Its researchers work closely with clinicians to ensure that scientific questions stay connected to what actually matters for patients.
Lead work packages 3, 5, 6 & 7
WP3: Generation of an Innovative MARCH-Based Degrader Platform for Identification of Onco-Therapeutic targets
WP5: Innovation Management and Exploitation
WP6: Dissemination, Communication and Stakeholder Engagement
WP7: Project coordination and management
Madelon Maurice
Title/role
Ingrid Jordens
Project manager
Fabiola de Andrade
Koninklijke Nederlandse Akademie van Wetenschappen, the Netherlands
KNAW is the Netherlands’ national academy of arts and sciences, and home to a number of independent research institutes. It supports fundamental research across disciplines and works to connect scientific knowledge to broader questions in society.
Lead work package 1
WP: Discovery and Engineering of High-Affinity Binders for MARCH-based Degraders
Danny Sahtoe
Universitatsklinkum Bonn, Germany
UKB is the university hospital of the University of Bonn, with active research programmes in immunology, oncology, and rare diseases. It combines a busy clinical environment with strong ties to basic science, making it well placed to work on questions that sit at the interface of the two.
Lead work package 2
WP2: Identification, characterization and optimization of bispecific MARCH-based degraders with highest potency
Florian Schmidt
Universitat zurich, Switzerland
UZH is Switzerland’s largest university, with a broad research portfolio spanning medicine, immunology, genetics, and structural biology. It is part of a dense scientific ecosystem in Zurich, with close collaborative ties to ETH Zurich and the University Hospital Zurich.
Lead work package 4
WP4: Assessment of the efficacy of MARCH-based SureTACs in pre-clinical patient-derived cancer models
Thorsten Zenz
Laigo Bio, the Netherlands
Laigo Bio is an innovative biotech company pioneering a new approach to treating cancer and autoimmune disease through targeted membrane protein degradation. Its SureTAC™ platform uses bispecific antibodies to guide the cell’s own recycling machinery towards disease-causing surface proteins, with the aim of degrading targets that have so far been difficult to drug.
